# Post-Authorization Safety Study (PASS) of conjugated estrogens/bazedoxifene (CE/BZA) in the United States

**First published:** 17/11/2015

**Last updated:** 22/02/2024

Study Finalised

## Administrative details

**EU PAS number**

EUPAS11599

**Study ID**

46641

**DARWIN EU® study**

No

**Study countries**

☐ United States

**Study description**

Compare the incidence of safety endpoints, in patients exposed to Duavee compared to estrogen + progestin (E+P) combination hormone replacement therapy (HRT) in the United States. This protocol describes a non-interventional study (NIS) designated as a Post-Authorization Safety Study (PASS) that will be conducted in the US in order to fulfill a post-authorization commitment to the European Medicines Agency (EMA).

**Study status**

Finalised

# Research institutions and networks

## Institutions

### HealthCore

**First published:** 01/02/2024

**Last updated:** 01/02/2024

**Institution**

# Contact details


**Study institution contact**

Renu Garg kofi.asomaning@pfizer.com

**Study contact**

kofi.asomaning@pfizer.com

**Primary lead investigator**

Renu Garg

**Primary lead investigator**

## Study timelines

**Date when funding contract was signed**
Planned: 23/10/2014

Actual: 23/10/2014

---

**Study start date**
Planned: 01/11/2015

Actual: 01/05/2014

---

**Data analysis start date**
Actual: 01/11/2015

---

**Date of final study report**
Planned: 31/03/2021

Actual: 31/03/2021

## Sources of funding

- Pharmaceutical company and other private sector

## More details on funding

Pfizer, Inc

## Study protocol

B2311060_Duavive US PASS FINAL Protocol CHMP ENDORSED 22OCT2015.pdf (1001.1 KB)

B2311060_Duavive US PASS FINAL Protocol CHMP ENDORSED 22OCT2015 AMENDED 21AUG2019_FINAL_clean (w-approval record).docx.pdf (7.21 MB)

## Regulatory

**Was the study required by a regulatory body?**

Yes

---

**Is the study required by a Risk Management Plan (RMP)?**

EU RMP category 3 (required)

# Methodological aspects

## Study type

## Study type list

**Study topic:**

Human medicinal product

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Assessment of risk minimisation measure implementation or effectiveness

Safety study (incl. comparative)

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

The overall aim of this PASS is to monitor the safety profile of Duavee in comparison to estrogen + progestin (E+P) combination hormone replacement therapies (HRT) in the US.

## Study Design

**Non-interventional study design**

Cohort

Other

---

**Non-interventional study design, other**

Post Authorization Safety Study (PASS)

## Study drug and medical condition

**Medicinal product name, other**

Duavee

---

**Medical condition to be studied**

Menopausal symptoms

## Population studied

**Short description of the study population**

Study subjects are all patients identified in each database with minimal exclusion criteria applied. This broad subject eligibility will ensure that the study is representative of the actual ‘real-world’ use of the product in a clinical setting.

Inclusion Criteria

All patients who have received a prescription for Duavee or E+P HT since May 2014 (date of
first commercial availability in the US) and have a baseline period of at least 12 months prior
to their first dispensing of a study medicine will be eligible for inclusion.

Primary Analyses

- To be included in the primary analyses, patients need to be new initiators of Duavee or E+P HT, as evidenced by a minimum 12 month baseline period with no prior use of either Duavee or E+P HT (including non-study estrogens).

Secondary Analyses

- To be included in the secondary analyses, patients will have use of either (1) single-entity estrogens or progestins (non-study drugs) or (2) unopposed estrogen
(single-entity estrogen without evidence of any progestin dispensing) in their baseline period.

Exclusion Criteria

Patients meeting any of the following criteria will be excluded from the study:

- Patients with <12 months of continuous enrollment prior to their dispensing of a study medication. This baseline period is necessary to determine if the patient is a new initiator of Duavee or E+P HT without a history of unopposed estrogen use, and to ascertain baseline covariates and medical history;

 Patients without a uterus, ie, males, or women for whom evidence of hysterectomy is identified prior to initiation of Duavee or comparator E+P HT; or
 Patients with a diagnosis or history of any cancer during their baseline period;
 Patients for whom Duavee, comparator E+P HT or unopposed estrogen are identified during the baseline period will be excluded from the primary analyses and will be evaluated in separate secondary analyses;
 Patients for whom cardiovascular outcomes are identified in the six months prior to the index date will be excluded from the analyses of cardiovascular outcomes.

---

**Age groups**

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- Adults (18 to < 46 years)
- Adults (46 to < 65 years)
- Adults (65 to < 75 years)
- Adults (75 to < 85 years)
- Adults (85 years and over)

---

**Estimated number of subjects**

13698

## Study design details

**Outcomes**

Endometrial hyperplasia and Endometrial cancer, VTE, CHD, stroke, breast cancer, ovarian cancer, thyroid cancer, renal cancer, renal adenoma, gastrointestinal tract cancers, all cancers, and all-cause mortality

---

**Data analysis plan**

Analyses will focus on the comparison between women initiating either Duavee or E+P HRT. Baseline characteristics will be compared across the two cohorts of new users to assess potential confounding variables. For each safety endpoint (venous thromboembolism VTE, stroke, coronary heart disease CHD, breast cancer, ovarian cancer, endometrial hyperplasia, and endometrial cancer, etc.), univariate and adjusted HRs will be estimated that compare incidence of the first occurrence of each safety event between Duavee and E+P HRT users.

## Documents

**Study results**

Duavive_B2311060_Final_Report_Abstract_fv.pdf (1.75 MB)

**Study report**

Duavive_B2311060_Final_Report_fv.pdf (4.22 MB)

# Data management

## ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

**Signed checklist for study protocols**

ENCEPP Protocol Checklist US PASS B2311060 SIGNED SUBMITTED 26JAN2015.pdf (1.54 MB)

## Data sources

**Data sources (types)**

Administrative healthcare records (e.g., claims)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Unknown

**Check completeness**

Unknown

**Check stability**

Unknown

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No